Anbio BiotechnologyNNNN
Price (close)
$6.15
Market cap
—
P/E
—
Revenue (FY)
$8.6M
Net income
$6.4M
Dividend yield
—
1-year total return
-82.8%
Net margin
74.1%
Revenue growth
5.6%
Debt / equity
—
What Anbio Biotechnology does.
of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics
landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim
to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $23.5M | $6.7M | $8.2M | $8.6M |
| Net income | — | $10.0M | $2.3M | $2.4M | $6.4M |
More on NNNN.
- Anbio Biotechnology summary
- Anbio Biotechnology financial statements
- Anbio Biotechnology key metrics
- Anbio Biotechnology health scores and style box
- Anbio Biotechnology earnings
- Anbio Biotechnology dividends
- Anbio Biotechnology valuation
- Anbio Biotechnology ownership and insiders
- Anbio Biotechnology peers
Figures from Anbio Biotechnology's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.